---
document_datetime: 2025-12-02 05:44:35
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/livtencity.html
document_name: livtencity.html
version: success
processing_time: 0.1265153
conversion_datetime: 2025-12-25 11:04:18.320352
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Livtencity

[RSS](/en/individual-human-medicine.xml/67617)

##### Authorised

This medicine is authorised for use in the European Union

maribavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Livtencity](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78622)
- [More information on Livtencity](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Livtencity is an antiviral medicine used to treat illness caused by cytomegalovirus (CMV) in adults who have had a haematopoietic stem cell transplant or an organ transplant. It is used in patients whose CMV illness has not responded to at least one other treatment, including ganciclovir, valganciclovir, cidofovir or foscarnet.

Haematopoietic stem cell transplantation involves using stem cells from a donor to replace the recipient's bone marrow cells. The donated stem cells will form new bone marrow that produces healthy blood cells.

CMV is a common virus that usually only causes mild infection in healthy people. After infection, the virus remains in the body in an inactive form and does not cause harm. However, CMV can become active and cause illness in patients whose immune system (the body's natural defences) is weakened, such as those who have had a stem cell or organ transplant.

CMV disease is rare, and Livtencity was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 December 2007 and 7 June 2013. Further information on the orphan designations can be found here: ema.europa.eu/medicines/human/orphan-designations/eu307519 and ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1133.

Livtencity contains the active substance maribavir.

Expand section

Collapse section

## How is Livtencity used?

Livtencity can only be obtained with a prescription and should be used according to official recommendations. Treatment should be started by a doctor experienced in managing patients who have had a haematopoietic stem cell or organ transplant.

Livtencity is available as tablets to be taken by mouth and the recommended dose is 400 mg twice a day for 8 weeks. Treatment duration may be adjusted depending on the patient's condition and response to treatment.

For more information about using Livtencity, see the package leaflet or contact your doctor or pharmacist.

## How does Livtencity work?

Maribavir, the active substance in Livtencity, blocks an enzyme (a type of protein) from CMV called UL97 protein kinase, which the virus needs to multiply. This stops the virus from multiplying and infecting other cells.

## What benefits of Livtencity have been shown in studies?

Livtencity was found to be more effective than other available CMV treatment at clearing CMV infection in adults who had undergone a stem cell or organ transplant and whose CMV infection had not responded to prior treatment. In a main study involving 352 adults, 56% (131 out of 235) of patients treated with Livtencity had undetectable levels of CMV after 8 weeks compared with 24% (28 out of 117) of those who received another CMV treatment chosen by their doctor.

## What are the risks associated with Livtencity?

The most common side effects with Livtencity (which may affect more than 1 in 10 people) are taste disturbance, nausea (feeling sick), diarrhoea, vomiting and tiredness.

Serious side effects (which may affect more than 1 in 100 people) include diarrhoea, nausea, vomiting, weight loss, tiredness, and increased blood levels of immunosuppressant medicine (a medicine used to reduce activity of the immune system).

For the full list of side effects of Livtencity, see the package leaflet.

Livtencity must not be used together with ganciclovir or valganciclovir (other antiviral medicines).

For the full list of restrictions of Livtencity, see the package leaflet.

## Why is Livtencity authorised in the EU?

Livtencity was effective at clearing CMV from the blood, and its safety profile is acceptable and more favourable than available treatments. The European Medicines Agency therefore decided that Livtencity's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Livtencity?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Livtencity have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Livtencity are continuously monitored. Suspected side effects reported with Livtencity are carefully evaluated and any necessary action taken to protect patients.

## Other information about Livtencity

Livtencity received a marketing authorisation valid throughout the EU on 9 November 2022.

Livtencity : EPAR - Medicine Overview

Reference Number: EMA/880622/2022

English (EN) (131.56 KB - PDF)

**First published:** 24/11/2022

[View](/en/documents/overview/livtencity-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-378)

български (BG) (159.02 KB - PDF)

**First published:**

24/11/2022

[View](/bg/documents/overview/livtencity-epar-medicine-overview_bg.pdf)

español (ES) (133.76 KB - PDF)

**First published:**

24/11/2022

[View](/es/documents/overview/livtencity-epar-medicine-overview_es.pdf)

čeština (CS) (155.28 KB - PDF)

**First published:**

24/11/2022

[View](/cs/documents/overview/livtencity-epar-medicine-overview_cs.pdf)

dansk (DA) (133.41 KB - PDF)

**First published:**

24/11/2022

[View](/da/documents/overview/livtencity-epar-medicine-overview_da.pdf)

Deutsch (DE) (136 KB - PDF)

**First published:**

24/11/2022

[View](/de/documents/overview/livtencity-epar-medicine-overview_de.pdf)

eesti keel (ET) (120.94 KB - PDF)

**First published:**

24/11/2022

[View](/et/documents/overview/livtencity-epar-medicine-overview_et.pdf)

ελληνικά (EL) (160.07 KB - PDF)

**First published:**

24/11/2022

[View](/el/documents/overview/livtencity-epar-medicine-overview_el.pdf)

français (FR) (134.56 KB - PDF)

**First published:**

24/11/2022

[View](/fr/documents/overview/livtencity-epar-medicine-overview_fr.pdf)

hrvatski (HR) (152.64 KB - PDF)

**First published:**

24/11/2022

[View](/hr/documents/overview/livtencity-epar-medicine-overview_hr.pdf)

italiano (IT) (130.73 KB - PDF)

**First published:**

24/11/2022

[View](/it/documents/overview/livtencity-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (169 KB - PDF)

**First published:**

24/11/2022

[View](/lv/documents/overview/livtencity-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (153.97 KB - PDF)

**First published:**

24/11/2022

[View](/lt/documents/overview/livtencity-epar-medicine-overview_lt.pdf)

magyar (HU) (155.65 KB - PDF)

**First published:**

24/11/2022

[View](/hu/documents/overview/livtencity-epar-medicine-overview_hu.pdf)

Malti (MT) (157.21 KB - PDF)

**First published:**

24/11/2022

[View](/mt/documents/overview/livtencity-epar-medicine-overview_mt.pdf)

Nederlands (NL) (132.22 KB - PDF)

**First published:**

24/11/2022

[View](/nl/documents/overview/livtencity-epar-medicine-overview_nl.pdf)

polski (PL) (157.52 KB - PDF)

**First published:**

24/11/2022

[View](/pl/documents/overview/livtencity-epar-medicine-overview_pl.pdf)

português (PT) (133.12 KB - PDF)

**First published:**

24/11/2022

[View](/pt/documents/overview/livtencity-epar-medicine-overview_pt.pdf)

română (RO) (155.61 KB - PDF)

**First published:**

24/11/2022

[View](/ro/documents/overview/livtencity-epar-medicine-overview_ro.pdf)

slovenčina (SK) (153.21 KB - PDF)

**First published:**

24/11/2022

[View](/sk/documents/overview/livtencity-epar-medicine-overview_sk.pdf)

slovenščina (SL) (152.93 KB - PDF)

**First published:**

24/11/2022

[View](/sl/documents/overview/livtencity-epar-medicine-overview_sl.pdf)

Suomi (FI) (131.09 KB - PDF)

**First published:**

24/11/2022

[View](/fi/documents/overview/livtencity-epar-medicine-overview_fi.pdf)

svenska (SV) (130.06 KB - PDF)

**First published:**

24/11/2022

[View](/sv/documents/overview/livtencity-epar-medicine-overview_sv.pdf)

Livtencity : EPAR - Risk Management Plan

English (EN) (814.94 KB - PDF)

**First published:** 24/11/2022

**Last updated:** 22/10/2025

[View](/en/documents/rmp/livtencity-epar-risk-management-plan_en.pdf)

## Product information

Livtencity : EPAR - Product Information

English (EN) (388 KB - PDF)

**First published:** 24/11/2022

**Last updated:** 05/08/2025

[View](/en/documents/product-information/livtencity-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-646)

български (BG) (734.17 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/bg/documents/product-information/livtencity-epar-product-information_bg.pdf)

español (ES) (399.34 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/es/documents/product-information/livtencity-epar-product-information_es.pdf)

čeština (CS) (647.31 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/cs/documents/product-information/livtencity-epar-product-information_cs.pdf)

dansk (DA) (357.34 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/da/documents/product-information/livtencity-epar-product-information_da.pdf)

Deutsch (DE) (448.5 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/de/documents/product-information/livtencity-epar-product-information_de.pdf)

eesti keel (ET) (387.63 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/et/documents/product-information/livtencity-epar-product-information_et.pdf)

ελληνικά (EL) (719.33 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/el/documents/product-information/livtencity-epar-product-information_el.pdf)

français (FR) (409.61 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/fr/documents/product-information/livtencity-epar-product-information_fr.pdf)

hrvatski (HR) (713.91 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/hr/documents/product-information/livtencity-epar-product-information_hr.pdf)

íslenska (IS) (446.47 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/is/documents/product-information/livtencity-epar-product-information_is.pdf)

italiano (IT) (492.14 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/it/documents/product-information/livtencity-epar-product-information_it.pdf)

latviešu valoda (LV) (700.09 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/lv/documents/product-information/livtencity-epar-product-information_lv.pdf)

lietuvių kalba (LT) (634.53 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/lt/documents/product-information/livtencity-epar-product-information_lt.pdf)

magyar (HU) (524.17 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/hu/documents/product-information/livtencity-epar-product-information_hu.pdf)

Malti (MT) (665.91 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/mt/documents/product-information/livtencity-epar-product-information_mt.pdf)

Nederlands (NL) (404.12 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/nl/documents/product-information/livtencity-epar-product-information_nl.pdf)

norsk (NO) (393.5 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/no/documents/product-information/livtencity-epar-product-information_no.pdf)

polski (PL) (665.32 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/pl/documents/product-information/livtencity-epar-product-information_pl.pdf)

português (PT) (399.21 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/pt/documents/product-information/livtencity-epar-product-information_pt.pdf)

română (RO) (731.76 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/ro/documents/product-information/livtencity-epar-product-information_ro.pdf)

slovenčina (SK) (652.8 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/sk/documents/product-information/livtencity-epar-product-information_sk.pdf)

slovenščina (SL) (621.23 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/sl/documents/product-information/livtencity-epar-product-information_sl.pdf)

Suomi (FI) (773.97 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/fi/documents/product-information/livtencity-epar-product-information_fi.pdf)

svenska (SV) (357.93 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

05/08/2025

[View](/sv/documents/product-information/livtencity-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254465 15/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Livtencity : EPAR - All authorised presentations

English (EN) (27.62 KB - PDF)

**First published:** 24/11/2022

**Last updated:** 16/01/2023

[View](/en/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-510)

български (BG) (29.88 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/bg/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.18 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/es/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.12 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/cs/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (29.39 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/da/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (28.15 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/de/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28.87 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/et/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (29.29 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/el/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_el.pdf)

français (FR) (27.57 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/fr/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.33 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/hr/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28.03 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/is/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.79 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/it/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (28.65 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/lv/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.52 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/lt/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.23 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/hu/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (29.06 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/mt/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (28.08 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/nl/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (28.69 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/no/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.27 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/pl/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_pl.pdf)

português (PT) (28.38 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/pt/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_pt.pdf)

română (RO) (28.27 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/ro/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.04 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/sk/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (28.2 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/sl/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (27.96 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/fi/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.7 KB - PDF)

**First published:**

24/11/2022

**Last updated:**

16/01/2023

[View](/sv/documents/all-authorised-presentations/livtencity-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Livtencity Active substance Maribavir International non-proprietary name (INN) or common name maribavir Therapeutic area (MeSH) Cytomegalovirus Infections Anatomical therapeutic chemical (ATC) code J05AX10

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

Consideration should be given to official guidance on the appropriate use of antiviral agents.

## Authorisation details

EMA product number EMEA/H/C/005787

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Takeda Pharmaceuticals International AG Ireland Branch

Block 2 Miesian Plaza

Opinion adopted 15/09/2022 Marketing authorisation issued 09/11/2022 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Livtencity : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (168.59 KB - PDF)

**First published:** 05/08/2025

**Last updated:** 22/10/2025

[View](/en/documents/procedural-steps-after/livtencity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Livtencity : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (151.68 KB - PDF)

**First published:** 16/01/2023

**Last updated:** 26/03/2024

[View](/en/documents/procedural-steps-after/livtencity-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Livtencity-H-C-005787-P46-002 : EPAR - Assessment report

Adopted

Reference Number: EMA/112993/2023

English (EN) (367.99 KB - PDF)

**First published:** 16/03/2023

[View](/en/documents/variation-report/livtencity-h-c-005787-p46-002-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Livtencity : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-911372

English (EN) (446.3 KB - PDF)

**First published:** 24/11/2022

[View](/en/documents/orphan-maintenance-report/livtencity-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Livtencity : EPAR - Public assessment report

Adopted

Reference Number: EMA/792160/2022

English (EN) (8.01 MB - PDF)

**First published:** 24/11/2022

[View](/en/documents/assessment-report/livtencity-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Livtencity

Adopted

Reference Number: EMA/CHMP/248091/2022

English (EN) (85.95 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop-initial/chmp-summary-opinion-livtencity_en.pdf)

#### News on Livtencity

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Livtencity : EPAR - Product information - tracked changes

English (EN) (133.46 KB - DOCX)

**First published:** 05/08/2025

[View](/en/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-413)

български (BG) (103.18 KB - DOCX)

**First published:**

05/08/2025

[View](/bg/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_bg.docx)

español (ES) (108.95 KB - DOCX)

**First published:**

05/08/2025

[View](/es/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_es.docx)

čeština (CS) (111.04 KB - DOCX)

**First published:**

05/08/2025

[View](/cs/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (101.5 KB - DOCX)

**First published:**

05/08/2025

[View](/da/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (108.16 KB - DOCX)

**First published:**

05/08/2025

[View](/de/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (103.54 KB - DOCX)

**First published:**

05/08/2025

[View](/et/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (115.63 KB - DOCX)

**First published:**

05/08/2025

[View](/el/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_el.docx)

français (FR) (112.3 KB - DOCX)

**First published:**

05/08/2025

[View](/fr/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (101.25 KB - DOCX)

**First published:**

05/08/2025

[View](/hr/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (96.18 KB - DOCX)

**First published:**

05/08/2025

[View](/is/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_is.docx)

italiano (IT) (103.71 KB - DOCX)

**First published:**

05/08/2025

[View](/it/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (109.56 KB - DOCX)

**First published:**

05/08/2025

[View](/lv/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (91.97 KB - DOCX)

**First published:**

05/08/2025

[View](/lt/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (108.52 KB - DOCX)

**First published:**

05/08/2025

[View](/hu/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (92.61 KB - DOCX)

**First published:**

05/08/2025

[View](/mt/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (108.06 KB - DOCX)

**First published:**

05/08/2025

[View](/nl/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (95.81 KB - DOCX)

**First published:**

05/08/2025

[View](/no/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_no.docx)

polski (PL) (103.25 KB - DOCX)

**First published:**

05/08/2025

[View](/pl/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_pl.docx)

português (PT) (102.74 KB - DOCX)

**First published:**

05/08/2025

[View](/pt/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_pt.docx)

română (RO) (104.02 KB - DOCX)

**First published:**

05/08/2025

[View](/ro/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (104.07 KB - DOCX)

**First published:**

05/08/2025

[View](/sk/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (92.42 KB - DOCX)

**First published:**

05/08/2025

[View](/sl/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (101.73 KB - DOCX)

**First published:**

05/08/2025

[View](/fi/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (105.35 KB - DOCX)

**First published:**

05/08/2025

[View](/sv/documents/product-information-tracked-changes/livtencity-epar-product-information-tracked-changes_sv.docx)

#### More information on Livtencity

- [EU/3/07/519 - orphan designation for prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity](/en/medicines/human/orphan-designations/eu-3-07-519)
- [EU/3/13/1133 - orphan designation for treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity](/en/medicines/human/orphan-designations/eu-3-13-1133)
- [EMEA-000353-PIP02-16-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000353-pip02-16-m03)
- [TAK-620-4007: Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000006)

**This page was last updated on** 22/10/2025

## Share this page

[Back to top](#main-content)